Different risk and prognostic factors for liver metastasis of breast cancer patients with de novo and relapsed distant metastasis in a Chinese population

被引:1
作者
Zhang, Ningning [1 ]
Xiang, Yimei [2 ]
Shao, Qing [1 ]
Wu, Jing [1 ]
Liu, Yumin [3 ]
Long, Hua [3 ]
Tao, Dan [4 ,5 ]
Zeng, Xiaohua [1 ,2 ,6 ]
机构
[1] Chongqing Univ, Dept Breast Canc Ctr, Canc Hosp, Chongqing, Peoples R China
[2] Chongqing Univ, Canc Hosp, Dept Breast Canc Ctr, Sch Med, Chongqing, Peoples R China
[3] Chongqing Univ, Dept Med Record, Canc Hosp, Chongqing, Peoples R China
[4] Chongqing Univ, Dept Radiat Oncol, Canc Hosp, Chongqing, Peoples R China
[5] Chongqing Univ, Chongqing Key Lab Translat Res Canc Metastasis & I, Canc Hosp, Chongqing, Peoples R China
[6] Chongqing Univ, Chongqing Key Lab Intelligent Oncol Breast Canc iC, Canc Hosp, Chongqing, Peoples R China
关键词
breast cancer; risk factors; liver metastasis; de novo distant metastasis; relapsed distant metastasis; prognosis; BIOLOGICAL SUBTYPES; HEPATIC METASTASES; STAGE IV; DIAGNOSIS; SURVIVAL; WOMEN; RESECTION; NOMOGRAM; FEATURES; OUTCOMES;
D O I
10.3389/fonc.2023.1102853
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe present study aimed to identify clinicopathological characteristics of breast cancer liver metastasis (BCLM) as well as to characterize the risk and prognostic factors for the liver metastasis (LM) of breast cancer patients with de novo and relapsed distant metastasis in a Chinese population. Materials and methodsPatients with metastatic breast cancer (MBC) who were hospitalized in the Breast Cancer Center at Chongqing University between January 2011 and December 2019 were included in the present study. Logistic regression analyses were conducted to identify risk factors for the presence of BCLM. Cox proportional hazard regression models were performed to determine the prognostic factors for the survival of BCLM patients. The correlation between LM and overall survival was assessed by the Kaplan-Meier method. ResultsIn total, 1,228 eligible MBC patients, including 325 cases (26.5%) with de novo metastasis (cohort A) and 903 cases (73.5%) with relapsed metastasis (cohort B), were enrolled in the present study. In cohort A and cohort B, 81 (24.9%) and 226 (25.0%) patients had BCLM, respectively. Patients in these two cohorts had different clinicopathological features. Logistic regression analysis identified that the human epidermal growth factor receptor 2 (HER2) status in cohort A as well as the HER2 status and invasive ductal carcinoma histology in cohort B were risk factors for BCLM. The median OS of patients with LM was inferior to that of non-LM patients (17.1 vs. 37.7 months, P = 0.0004 and 47.6 vs. 84.0 months, P < 0.0001, respectively). Cox analysis identified that the primary T stage, Ki67 level, and breast surgery history were independent prognostic factors for cohorts A and B, respectively. ConclusionsDe novo and relapsed MBC patients have different risk and prognostic factors for LM. Patients with BCLM have an unfavorable prognosis.
引用
收藏
页数:14
相关论文
共 51 条
[1]   Is liver resection justified for patients with hepatic metastases from breast cancer? [J].
Adam, Rene ;
Aloia, Thomas ;
Krissat, Jinane ;
Bralet, Marie-Pierre ;
Paule, Bernard ;
Giacchetti, Sylvie ;
Delvart, Valerie ;
Azoulay, Daniel ;
Bismuth, Henri ;
Castaing, Denis .
ANNALS OF SURGERY, 2006, 244 (06) :897-908
[2]   ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer [J].
Arciero, Cletus A. ;
Guo, Yi ;
Jiang, Renjian ;
Behera, Madhusmita ;
O'Regan, Ruth ;
Peng, Limin ;
Li, Xiaoxian .
CLINICAL BREAST CANCER, 2019, 19 (04) :236-245
[3]   Local Treatment of Breast Cancer Liver Metastasis [J].
Bale, Reto ;
Putzer, Daniel ;
Schullian, Peter .
CANCERS, 2019, 11 (09)
[4]   Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].
Bardia, A. ;
Hurvitz, S. A. ;
Tolaney, S. M. ;
Loirat, D. ;
Punie, K. ;
Oliveira, M. ;
Brufsky, A. ;
Sardesai, S. D. ;
Kalinsky, K. ;
Zelnak, A. B. ;
Weaver, R. ;
Traina, T. ;
Dalenc, F. ;
Aftimos, P. ;
Lynce, F. ;
Diab, S. ;
Cortes, J. ;
O'Shaughnessy, J. ;
Dieras, V ;
Ferrario, C. ;
Schmid, P. ;
Carey, L. A. ;
Gianni, L. ;
Piccart, M. J. ;
Loibl, S. ;
Goldenberg, D. M. ;
Hong, Q. ;
Olivo, M. S. ;
Itri, L. M. ;
Rugo, H. S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541
[5]   Breast Cancer Treatments: Updates and New Challenges [J].
Burguin, Anna ;
Diorio, Caroline ;
Durocher, Francine .
JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (08)
[6]   Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015) [J].
Cardoso, Fatima ;
Spence, Danielle ;
Mertz, Shirley ;
Corneliussen-James, Dian ;
Sabelko, Kimberly ;
Gralow, Julie ;
Cardoso, Maria-Joao ;
Peccatori, Fedro ;
Paonessa, Diego ;
Benares, Ann ;
Sakurai, Naomi ;
Beishon, Marc ;
Barker, Sarah-Jane ;
Mayer, Musa .
BREAST, 2018, 39 :131-138
[7]   Unique features of breast cancer in Taiwan [J].
Cheng, SH ;
Tsou, MH ;
Liu, MC ;
Jian, JJ ;
Cheng, JCH ;
Leu, SY ;
Hsieh, CY ;
Huang, AT .
BREAST CANCER RESEARCH AND TREATMENT, 2000, 63 (03) :213-223
[8]   Prospective Observational Study of Breast Cancer Treatment Outcomes for UK Women Aged 1840 Years at Diagnosis: The POSH Study [J].
Copson, Ellen ;
Eccles, Bryony ;
Maishman, Tom ;
Gerty, Sue ;
Stanton, Louise ;
Cutress, Ramsey I. ;
Altman, Douglas G. ;
Durcan, Lorraine ;
Simmonds, Peter ;
Lawrence, Gill ;
Jones, Louise ;
Bliss, Judith ;
Eccles, Diana .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (13) :978-988
[9]   Metastatic progression of breast cancer: insights from 50 years of autopsies [J].
Cummings, Margaret C. ;
Simpson, Peter T. ;
Reid, Lynne E. ;
Jayanthan, Janani ;
Skerman, Joanna ;
Song, Sarah ;
Reed, Amy E. McCart ;
Kutasovic, Jamie R. ;
Morey, Adrienne L. ;
Marquart, Louise ;
O'Rourke, Peter ;
Lakhani, Sunil R. .
JOURNAL OF PATHOLOGY, 2014, 232 (01) :23-31
[10]   Survival differences among women with de novo stage IV and relapsed breast cancer [J].
Dawood, S. ;
Broglio, K. ;
Ensor, J. ;
Hortobagyi, G. N. ;
Giordano, S. H. .
ANNALS OF ONCOLOGY, 2010, 21 (11) :2169-2174